The goal of the CTCA REVIEW is to efficiently discuss the most recent clinical
advances and trials in the rapidly evolving field of malignant hematology and oncology. This program is
unique in addressing the questions and controversies that have emerged from the latest data
presented at both the American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) annual
After attending the CTCA REVIEW, participants should be able to:
- Interpret new and emerging data presented at the ASH and ASCO
- Incorporate newer evidence-based data to assess the care of patients
- Incorporate knowledge gained into appropriate management strategies to
improve outcomes in patients with cancer
- Utilize current standards of care for patients with
The CTCA REVIEW will be of interest to healthcare providers involved in the care
of oncology patients, including medical oncologists, hematologists, surgical oncologists, radiation oncologists,
diagnostic radiologists, pathologists, oncology fellows, resident trainees, primary care providers, advanced care
practitioners, physician assistants, nurses, chiropractors, naturopathic physicians, and pharmacists.
- Interactive Presentations
- Patient Case Presentations
- Faculty Panel Discussion
- Question and Answer Sessions
- Program Syllabus
A course evaluation form will be provided to CTCA REVIEW participants to have the
opportunity to comment on any perceived commercial bias in the presentations, as well as to identify future
educational topics. In addition, participants will have the opportunity to comment on the value of the program
content on their practice decisions, performance improvement activities, or possible impact on patient health
This activity has been planned and implemented in accordance with the Essential Areas and policies of the
Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Dannemiller and
Athena Education Group. Dannemiller is accredited by the ACCME to provide continuing medical education for
Dannemiller designates this live activity for a maximum of 8.5 AMA PRA
Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their
participation in the program.
Dannemiller is a provider approved by the California Board of Registered Nursing, Provider Number 4229. This
activity has been approved for 8.5 contact hours.
Please Note: RNs outside California must verify with their licensing agency for
approval of this course.
As a provider accredited by ACCME, Dannemiller must ensure balance, independence, objectivity and scientific
rigor in its educational activities. Course director(s), planning committee, faculty, and all others who are in a
position to control the content of this educational activity are required to disclose all relevant financial
relationships with any commercial interest related to the subject matter of the educational activity. Safeguards
against commercial bias have been put in place. Faculty also will disclose any off-label and/or investigational use
of pharmaceuticals or instruments discussed in their presentation. Disclosure of this information will be published
in course materials so those participants in the activity may formulate their own judgment regarding the
Dannemiller is accredited by the Accreditation Council for
Pharmacy Education as a provider of contuining pharmacy education. This activity is a knowledge based
activity. Dannemiller has assigend 8.5 contact hours (.85 CEU) of continuing pharmacy education credit for
participation in this activity. ACPE program nubmer 0522-9999-13-L01-P.
CME Certificates and Attendance Verification
Certificates awarding AMA PRA Category 1 Credit™ or certificates
documenting attendance will be distributed to participants when an individual departs from the conference. To
obtain a CME or CE certificate, healthcare providers must submit a completed evaluation questionnaire and a CME/CE
Upon request, a record of attendance certificate will be provided onsite to other
oncology care professionals for requesting credits in accordance with state nursing boards, specialty societies, or
other professional associations.
Unapproved Uses of Drugs/Devices
In accordance with requirements of the Food and Drug Administration (FDA), the
audience is advised that informaton presented in this continuing medical education activity may contain references
to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for
each drug/device for full prescribing information.
American’s with Disabilities Act (ADA)
Dannemiller and Athena fully comply with the legal requirements of the ADA and the
rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please
contact Sue at email@example.com by July 1,
2013 in order to receive appropriate services at the conference.
For More Information
Athena Education Group, LLC
Attention: Nike Gazonas
River Walk, Building A
201 South Main Street, Suite 15
Lambertville, NJ USA 08530
Jointly sponsored by Dannemiller and Athena Education Group.
Dannemiller and Athena Education Group gratefully acknowledge an educational grant from the Cancer Treatment
Centers of America® in support of this continuing education
*This review course is not an official program of ASH or ASCO, nor is it endorsed by ASH or ASCO.